ArticleInternational journal of women's health2026
Combined Assessment of EZH2 and EGFR as Potential Diagnostic Biomarkers for Epithelial Ovarian Tumors: Bioinformatics Analysis and Clinical Validation.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study was to investigate the expression and clinical significance of Enhancer of Zeste Homolog 2 (EZH2) and Epidermal Growth Factor Receptor (EGFR) in epithelial ovarian cancer (EOC). Methods: EZH2 and EGFR in EOC were analysed by bioinformatics. Samples from 55 patients with epithelial ovarian tumors (22 malignant, 14 borderline, and 19 benign) and 10 normal ovarian tissue were collected, EZH2 and EGFR expression levels were measured by immunohistochemistry (IHC) and Enzyme-Linked Immunosorbent Assay (ELISA). Results: Public-database analyses indicated increased EZH2 but decreased EGFR expression in ovarian serous cystadenocarcinoma relative to normal ovarian tissue ( Conclusion: EZH2 and EGFR are highly expressed and have diagnostic value for EOC, combined detection offered superior diagnostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.